Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8504120 | 0.95 | CA4 (0.56) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| Lithium Ion SCHEMBL8506314 | 0.95 | CA4 (0.50) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| Zinc Ion SCHEMBL16546436 | 0.95 | CA4 (0.50) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL6739148 | 0.95 | CA4 (0.50) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| Silver SCHEMBL6739147 | 0.95 | CA4 (0.50) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| Potassium Ion SCHEMBL8502230 | 0.95 | CA4 (0.50) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| Water SCHEMBL31011749 | 0.92 | CA4 (0.48) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL8615649 | 0.90 | CA4 (0.46) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL8615644 | 0.90 | CA4 (0.46) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL8614166 | 0.80 | CA1 (0.38) | CA4FFAR3HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080160101-A1 | Comprising antagonistic micro-organism and at least one salt and/or derivatives; biopesticide particularly useful against pathogens able to cause diseases to plant material | BIONEXT (BE) | 2008-07-03 | — | — | US | claimed |
| EP-1802196-A1 | COMPOSITIONS FOR USE AGAINST ONE OR MORE PATHOGENS | Bionext (BE) | 2007-07-04 | — | — | EP | claimed |
| WO-2006032530-A1 | COMPOSITIONS FOR USE AGAINST ONE OR MORE PATHOGENS | BIONEXT (BE) | 2006-03-30 | — | — | WO | claimed |
| CN-113234214-B | Copolyester and preparation method thereof | 中国科学院大连化学物理研究所 | 2022-02-15 | — | — | CN | disclosed |
| CN-113861396-A | Copolyester and preparation method thereof | 中国科学院大连化学物理研究所 | 2021-12-31 | — | — | CN | disclosed |
| CN-113234214-A | Copolyester and preparation method thereof | 中国科学院大连化学物理研究所 | 2021-08-10 | — | — | CN | disclosed |
| US-8828450-B2 | Compositions for use against one or more pathogens | BIONEXT (BE) | 2014-09-09 | — | — | US | disclosed |
| CN-101031203-B | Use of compositions for resisting against one or more pathogens | BIONEXT | 2011-05-11 | — | — | CN | disclosed |
| US-20080160101-A1 | Comprising antagonistic micro-organism and at least one salt and/or derivatives; biopesticide particularly useful against pathogens able to cause diseases to plant material | BIONEXT (BE) | 2008-07-03 | — | — | US | disclosed |
| CN-101031203-A | Compositions for use against one or more pathogens | BIONEXT (BE) | 2007-09-05 | — | — | CN | disclosed |
| EP-1802196-A1 | COMPOSITIONS FOR USE AGAINST ONE OR MORE PATHOGENS | Bionext (BE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006032530-A1 | COMPOSITIONS FOR USE AGAINST ONE OR MORE PATHOGENS | BIONEXT (BE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080160101-A1 | Comprising antagonistic micro-organism and at least one salt and/or derivatives; biopesticide particularly useful against pathogens able to cause diseases to plant material | CHIT1, MAN2A1, MANBA | HMGCR 2709/4885CA4 1917/4885CHRM1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.